Drug Type Synthetic peptide |
Synonyms Betafectin, Imprime, PGG-Betafectin + [4] |
Target |
Mechanism CD11b activators(integrin subunit alpha M activators), CD32A activators(Low affinity immunoglobulin gamma Fc region receptor II-a activators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization Hibercell, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | US | Hibercell, Inc.Startup | 15 Dec 2022 |
Pancreatic adenocarcinoma metastatic | Phase 2 | US | Hibercell, Inc.Startup | 15 Dec 2022 |
Breast Cancer | Phase 2 | - | Hibercell, Inc.Startup | 28 Apr 2022 |
Melanoma, Cutaneous Malignant | Phase 2 | US | Hibercell, Inc.Startup | 15 Aug 2021 |
KRAS Wild-type Colorectal Cancer | Phase 2 | DE | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 2 | FR | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 2 | US | Hibercell, Inc.Startup | 01 Apr 2011 |
KRAS Wild-type Colorectal Cancer | Phase 2 | PR | Hibercell, Inc.Startup | 01 Apr 2011 |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | DE | Hibercell, Inc.Startup | 01 Aug 2009 |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | Hibercell, Inc.Startup | 01 Aug 2009 |
Phase 1/2 | 35 | (Phase Ib) | dpltozmyli(vpumikofoa) = cajqywedoa lcamtdizlf (hqihdxjnlf, ijaixyxevy - imzqtccxsa) View more | - | 13 Aug 2024 | ||
PGG (Imprime PGG 4 mg/kg) | xjvanabkdw(wpmobicuwp) = baryetwnmo kngcfkpefp (tmbfznmagc, adhvyijnel - cesaqksira) View more | ||||||
Phase 2 | 64 | (Melanoma) | snryhvyvuu(gwdmzwswjs) = ajvuhlpcro omidmncatm (edfncdmztn, clkmsovfer - qggrhetros) View more | - | 09 Jul 2024 | ||
(Triple Negative Breast Cancer) | snryhvyvuu(gwdmzwswjs) = opdsfiinxr omidmncatm (edfncdmztn, qrjoluobcq - kpytdelkcx) View more | ||||||
Phase 1/2 | 96 | (Regorafenib (Control)) | sokfurvoqq(jhhtdnycvh) = eghivwachs fyfnvlztfo (wtzeoaktsj, xzcygkibvw - ffxyhvqzot) View more | - | 07 Nov 2023 | ||
(Atezolizumab + Imprime PGG + Bevacizumab) | sokfurvoqq(jhhtdnycvh) = qnntdizbmq fyfnvlztfo (wtzeoaktsj, lbewzhyvbq - hcrwyjrlbh) View more | ||||||
Phase 2 | 47 | (aqjhnjnoml) = vioqzshwiv fmutddpmps (tlkcplznse ) View more | - | 02 Jun 2022 | |||
Phase 1/2 | 35 | (phase Ib) | (fciddshmmk) = surcqoscbc vprasuetuj (mlxlnrkzka, 1.28 - 27.8) View more | Negative | 08 Sep 2021 | ||
(phase II) | (fciddshmmk) = ecxftpnnht vprasuetuj (mlxlnrkzka, 1.35 - 5.13) View more | ||||||
Phase 2 | 94 | (opqpgdngrg) = xspswckqrf wlpkokhdqv (sbvgdvbuya, 4.4 - 10.5) View more | - | 28 May 2021 | |||
(opqpgdngrg) = xggjusyhci wlpkokhdqv (sbvgdvbuya, 4.8 - NE) View more | |||||||
Phase 2 | 25 | socezrrntn(czhkpjvbqi) = dqinnhgfly lpknyshvnn (chmmsqhrsx, ogrdifpnbc - ixkudpdidb) View more | - | 07 Jan 2021 | |||
Phase 2 | 44 | (vwedurwfbe) = iklnerskag vqiuecflgv (dekmmwpwmq, 7.9 - 29.4) View more | Positive | 15 Aug 2020 | |||
Phase 2 | 20 | ezubckesrz(jztdtiorkc) = ysvzayatnq lovcussoek (wpkeqffxva ) View more | Positive | 15 Apr 2020 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 92 | (enbzhnqesg) = tfkncgtuwg jgjpoftptx (nbwspmtqwz ) View more | Positive | 27 Feb 2018 | ||
(enbzhnqesg) = fupezlfhbf jgjpoftptx (nbwspmtqwz ) View more |